On-demand video webcast now available
here
HOUSTON, March 11,
2025 /PRNewswire/ -- Moleculin Biotech,
Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company") a
late-stage pharmaceutical company with a broad portfolio of drug
candidates targeting hard-to-treat tumors and viruses, today
announced it participated in the Virtual Investor "Top 5 for '25"
On-Demand Conference.
As part of the event, Walter
Klemp, Chairman and Chief Executive Officer of Moleculin,
presented the top five reasons of why he believes the investment
community and industry colleagues should pay attention to Moleculin
in 2025.
The on-demand video webcast is now accessible for
viewing here and on the Events page in the Investors section
of the Company's website (moleculin.com).
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a Phase 3 clinical stage
pharmaceutical company advancing a pipeline of therapeutic
candidates addressing hard-to-treat tumors and viruses. The
Company's lead program, Annamycin, is a next-generation
anthracycline designed to avoid multidrug resistance mechanisms and
to eliminate the cardiotoxicity common with currently prescribed
anthracyclines. Annamycin is currently in development for the
treatment of relapsed or refractory acute myeloid leukemia (AML)
and soft tissue sarcoma (STS) lung metastases.
The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC
Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design
Phase 3 trial evaluating Annamycin in combination with cytarabine,
together referred to as AnnAraC, for the treatment of relapsed or
refractory acute myeloid leukemia. Following a successful Phase
1B/2 study (MB-106), with input from
the FDA, the Company believes it has substantially de-risked the
development pathway towards a potential approval for Annamycin for
the treatment of AML. This study is subject to appropriate future
filings with potential additional feedback from the FDA and their
foreign equivalents.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers. Moleculin is also engaged in the development of a
portfolio of antimetabolites, including WP1122 for the potential
treatment of pathogenic viruses, as well as certain cancer
indications.
For more information about the Company, please visit
www.moleculin.com and connect on X, LinkedIn and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-biotech-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference-302397299.html
SOURCE Moleculin Biotech, Inc.
